Basking Biosciences, Inc., is developing the first reversible thrombolytic therapy for Acute Ischemic Stroke (AIS). Dr. Bruce Sullenger of Duke University and Dr. Shahid Nimjee, of Ohio State University founded the company to commercialize aptamers with high affinity and specificity against proteins involved in coagulation and hemostasis.